TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

British Journal of Pharmacology

Volumn 164, Issue 1, 2011, Pages 181-191

  Yamamoto, K ^a   Uchida, S ^a   Kitano, K ^a   Fukuhara, N ^a   Okumura Kitajima, L ^a   Gunji, E ^a   Kozakai, A ^a   Tomoike, H ^a   Kojima, N ^a   Asami, J ^a   Toyoda, H ^a   Arai, M ^a   Takahashi, T ^a   Takahashi, K ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

anti diabetic agent; renal tubules; SGLT2 inhibitor; sodium glucose cotransporter; TS 071; type 2 diabetes mellitus; urinary glucose excretion

Indexed keywords

1,5 ANHYDRO 1 [5 [4 ETHOXYBENZYL] 2 METHOXY 4 METHYLPHENYL] 1 THIO DEXTRO GLUCITOL HYDRATE; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TS 071; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIHYPERGLYCEMIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL LINE; CHO K1 CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; TIME TO MAXIMUM PLASMA CONCENTRATION; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; CHO CELLS; CRICETINAE; CRICETULUS; DEOXYGLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DOGS; GLYCOSURIA; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL;

EID: 79961228970     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01340.x     Document Type: Article

References (21)

1. th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Calderhead DM, Kitagawa K, Tanner LI, Holman GD, Lienhard GE, (1990). Insulin regulation of the two glucose transporters in 3T3-L1 adipocytes. J Biol Chem 265: 13800-13808.
3. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J, (2005). Phlorizin: a review. Diabetes Metab Res Rev 21: 31-38.
4. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M, (2008). Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327: 268-276.
5. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al,. (2008). Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723-1729.
6. Hediger MA, Rhoads DB, (1994). Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74: 993-1026. (Pubitemid 24328943)
7. Inzucchi SE, (2002). Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287: 360-372. (Pubitemid 34256388)
8. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y, et al,. (2010). (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl] -1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53: 3247-3261.
9. +/glucose cotransporter SGLT2, Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93: 397-404.
10. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, et al,. (2007). Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320: 323-330. (Pubitemid 46025747)
11. Niwa H, Yamamura K, Miyazaki J, (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
12. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48: 1794-1800. (Pubitemid 29415199)
13. Olson AL, Pessin JE, (1996). Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16: 235-256. (Pubitemid 26286854)
14. Rakieten N, Rakieten ML, Nadkarni MV, (1963). Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29: 91-98.
15. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al,. (2003). Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14: 2873-2882. (Pubitemid 37305650)
16. Silverman M, Turner RJ, (1992). Glucose transport in the renal proximal tubule. In:, Windhager EE, (ed.). Handbook of Physiology, Section 8: Renal Physiology Vol. 2. Oxford University Press: Oxford, pp. 2017-2038.
17. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, et al,. (2011). SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-112.
18. +-glucose cotransporters. Am J Physiol Renal Physiol 280: F10-F18.
19. Wright EM, Turk E, Martin MG, (2002). Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys 36: 115-121. (Pubitemid 41270716)
20. +-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270: 29365-29371.
21. +/glucose cotransporter 1 (SGLT1). J Cell Biochem 90: 339-346. (Pubitemid 37222202)